Atrium Therapeutics, Inc. Common Stock
$ 12.25
-3.39%
02 Jun - close price
- Market Cap 216,900,000 USD
- Current Price $ 12.25
- High / Low $ 12.59 / 12.20
- Stock P/E N/A
- Book Value 13.69
- EPS -5.02
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -3.99 %
- ROE -0.44 %
- 52 Week High 16.77
- 52 Week Low 11.95
About
Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.
Analyst Target Price
$25.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-02-26 | 2025-11-10 | 2025-08-07 | 2025-05-08 | 2025-02-26 | 2024-11-07 | 2024-08-09 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.97 | -1.59 | -1.27 | -1.21 | -0.9 | -0.8 | -0.65 | -0.65 | -0.79 | -0.79 | -0.71 | -0.66 |
| Estimated EPS | -1.05 | -1.26 | -1.1 | -0.96 | -0.88 | -0.7809 | -0.72 | -0.78 | -0.88 | -0.66 | -0.75 | -0.79 |
| Surprise | 0.08 | -0.33 | -0.17 | -0.25 | -0.02 | -0.0191 | 0.07 | 0.13 | 0.09 | -0.13 | 0.04 | 0.13 |
| Surprise Percentage | 7.619% | -26.1905% | -15.4545% | -26.0417% | -2.2727% | -2.4459% | 9.7222% | 16.6667% | 10.2273% | -19.697% | 5.3333% | 16.4557% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RNA
2026-05-15 21:39:44
Leerink Partners has set a price target of $25.00 per share for Avidity Biosciences (NASDAQ: RNA). This new target suggests a potential for significant movement in the company's stock, according to the analyst firm. Investors will likely be watching how Avidity Biosciences reacts to this updated valuation.
2026-05-15 20:39:27
Avidity Biosciences (RNAM) has filed a Schedule 13G/A, an amendment by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah. This filing updates their beneficial ownership, indicating positions equal to or below 5% of the class as of March 31, 2026. The reporting persons collectively disclaim status as a "group," emphasizing that their disclosures are individual rather than collaborative for control purposes.
2026-04-29 12:40:01
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is projected for significant growth between 2020 and 2034, driven by increasing prevalence and a robust pharmaceutical pipeline. Key companies like Dyne Therapeutics, Avidity Biosciences, and Fulcrum Therapeutics are developing late-stage therapies, including gene-targeting treatments and Antibody Oligonucleotide Conjugates (AOCs™). The market is seeing considerable advancements in clinical trials, with several candidates showing promise in reducing DUX4 gene expression and improving patient outcomes, with a large unmet need for treatments.
2026-04-29 12:39:22
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is poised for rapid expansion, driven by an increasing prevalence of the disease and a robust pharmaceutical pipeline. Key companies like Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, and Fulcrum Therapeutics are developing therapies such as DYNE-301, MC-DX4, and Losmapimod, with several candidates showing promising clinical results, including Sarepta Therapeutics' siRNA programs and Avidity Biosciences' delpacibart braxlosiran. The market's growth is further supported by governmental efforts to facilitate research and a high likelihood of reimbursement for upcoming therapies, given the current lack of approved treatments for FSHD.
2026-04-29 02:39:38
Sarah Boyce is the President and CEO of Avidity Biosciences, a role she has held since October 2019. With over 25 years of leadership experience in the pharmaceutical and biopharmaceutical industries, she has been crucial in transforming Avidity from a research-focused company into a clinical-stage firm. Her leadership has guided the company through significant milestones, including funding rounds and an IPO, while advancing multiple RNA therapies into clinical development.
2026-03-27 02:38:50
Linklaters advised a global underwriting syndicate on an USD 11 billion SEC-registered bond issuance by Novartis. The proceeds will be used for general corporate purposes and to repay a bridge loan that financed Novartis' USD 12 billion acquisition of Avidity Biosciences. The international Linklaters team was led by Marco Carbonare, Kevin Roy, and Danelle Le Cren.
